A-Mycin Powder for Suspension: After reconstitution each 5 ml suspension contains Erythromycin Ethylsuccinate USP equivalent to 125 mg of Erythromycin. A-Mycin DS Powder for Suspension: After reconstitution each 5 ml suspension contains Erythromycin Ethylsuccinate USP equivalent to 250 mg of Erythromycin. A-Mycin Paediatric Drops: After reconstitution each 5 ml suspension contains Erythromycin Ethylsuccinate USP equivalent to 200 mg of Erythromycin.

A-Mycin is highly effective in the treatment of a wide variety of clinical infections, such as 1.Upper respiratory tract infections: Tonsillitis, peritonsillar abscess, pharyngitis, laryngitis, sinusitis, and secondary infections in cold and influenza. 2.Lower respiratory tract infections: Tracheitis, acute and chronic bronchitis. Mycoplasma pneumoniae (lobar pneumonia, broncho pneumonia, primary atypical pneumoniae), bronchiectasis. 3.Skin and soft tissue infections: Boils and carbuncles, paronychia, abscesses, pustular acne, impetigo, cellulitis, furuncolosis, erythrasma. 4.Veneral infections: Non-specific urethritis, syphilis (if the patient is allergic to penicillin). 5.Gastro-intestinal infections: Cholecystitis, Staphylococcal enterocolitis, infectious diarrhoea, & cholera. 6.Ear and oral infections: 0titis media and otitis externa, gingivitis, dental abscesses. 7.Prophylaxis: Pre-operative and post-operative, trauma, burns, rheumatic fever. 8.Other infections: Diphtheria, whooping cough.

Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Infections	Dosage and Administration
Upper respiratory tract infections of mild to moderate severity	250 to 500 mg 4 times a day for 10 days
Lower respiratory infections of mild to moderate severity	250 to 500 mg 4 times a day for 10 days
Respiratory tract infections due to Mycoplasma pneumoniae	500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks
Skin and soft tissue infections of mild to moderate severity	250 to 500 mg 4 times a day for 10 days
Pelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae	500 mg 4 times a day for 10 to 14 days
Urogenital infection during pregnancy caused by Chlamydia trachomatis	500 mg 4 times daily for 7 days or \n250 mg 4 times daily for 14 days
Urethral, endocervical or rectal infections, uncomplicated	500 mg 4 times daily for 7 days or \n250 mg 4 times daily for 14 days
Non-gonococcal urethritis	500 mg 4 times daily for at least 7 days
Neisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG)	500 mg 4 times a day for 7 days
Early syphillis (primary, secondary or latent syphillis of < 1 year duration)	500 mg 4 times a day for 14 days
Severe or chronic diarrhoea	500 mg 4 times a day for 7 days
Rheumatic fever	250 mg 2 times daily
Bacterial endocarditis	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose
Acne	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months

\nChildren: The usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled.

Erythromycin is contraindicated in patients with known hypersensitivity of this antibiotic.

Erythromycin should be used with care in patients with existing hepatic impairment. It has been suggested that Erythromycin should be used with care in patients with history of arrhythmia.

Gastro-intestinal: Abdominal cramp & discomfort, nausea, vomiting & diarrhoea. Hypersensitivity reaction may also be responsible for the hepatotoxicity sometimes in patients receiving Erythromycin or its derivatives.

A-Mycin (Erythromycin) may decrease the clearance of theophylline causing increased theophylline serum level and potential toxicity. It may decrease the metabolism of carbamazepine, triazolam, hexobarbital and phenytoin causing increased serum levels and potential toxicity. A-Mycin (Erythromycin) may decrease the clearance of warfarin and thus potentiate the hypoprothrombinic effect of warfarin.

Use in pregnancy: A-Mycin (Erythromycin) crosses the placenta. Fetal plasma concentrations are variously stated to the 5 to 20% of these in the mother. Use in lactation: It is readily excreted in breast milk.

A-Mycin Powder for Suspension: Bottle containing dry powder for reconstitution of 100 ml suspension. A-Mycin DS Powder for suspension: Bottle containing dry powder for reconstitution of 100 ml suspension. A-Mycin Paediatric Drops: Bottle containing dry powder for reconstitution of 60 ml suspension with dropper.